Biomarkers of lymphoma in Sjögren’s syndrome: what’s the latest?

References

• Goules AV, Tzioufas AG. Primary Sjӧgren’s syndrome: clinical phenotypes, outcome and the development of biomarkers. Autoimmun Rev. 2016 Jul;157(7):695–703.
   Google Scholar
• Shiboski CH, Shiboski SC, Seror R, et al. American College of Rheumatology/European League Against Rheumatism Classification Criteria for Primary Sjögren’s syndrome: a consensus and data-driven methodology involving three international patient cohorts. Arthritis Rheumatol. 2016 Jan;691:35–45. 2017
   Google Scholar
• Shiboski SC, Shiboski CH, Criswell L, et al. American College of Rheumatology classification criteria for Sjögren’s syndrome: a data-driven, expert consensus approach in the Sjögren’s international collaborative clinical alliance cohort. Arthritis Care Res (Hoboken). 2012 Apr;644(4):475–487.
   Google Scholar
• Vitali C, Bombardieri S, Jonsson R, et al. Classification criteria for Sjögren’s syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis. 2002 Jun;616(6):554–558.
   Google Scholar
• Goules AV, Tatouli IP, Moutsopoulos HM, et al. Clinically significant renal involvement in primary Sjögren’s syndrome: clinical presentation and outcome. Arthritis Rheum. 2013 Nov;6511(11):2945–2953.
   Google Scholar
• Kampolis CF, Fragkioudaki S, Mavragani CP, et al. Prevalence and spectrum of symptomatic pulmonary involvement in primary Sjögren’s syndrome. Clin Exp Rheumatol. 2018 May-Jun;36(3):94–101.
   PubMed Web of Science ®Google Scholar
• Moutsopoulos HM. Sjögren’s syndrome: autoimmune epithelitis. Clin Immunol Immunopathol. 1994 Aug;722(2):162–165.
   Google Scholar
• DiGiuseppe JA, Corio RL, Westra WH. Lymphoid infiltrates of the salivary glands: pathology, biology and clinical significance. Curr Opin Oncol. 1996 May;83(3):232–237.
   Google Scholar
• Ioannidis JP, Vassiliou VA, Moutsopoulos HM. Long-term risk of mortality and lymphoproliferative disease and predictive classification of primary Sjögren’s syndrome. Arthritis Rheum. 2002 Mar;463(3):741–747.
   Google Scholar
• Skopouli FN, Dafni U, Ioannidis JP, et al. Clinical evolution, and morbidity and mortality of primary Sjögren’s syndrome. Semin Arthritis Rheum. 2000 Apr;295(5):296–304.
   Google Scholar
• Pavlakis PP, Alexopoulos H, Kosmidis ML, et al. Peripheral neuropathies in Sjögren’s syndrome: a critical update on clinical features and pathogenetic mechanisms. J Autoimmun. 2012 Aug;391-2(1–2):27–33.
   Google Scholar
• Goules A, Masouridi S, Tzioufas AG, et al. Clinically significant and biopsy-documented renal involvement in primary Sjögren syndrome. Medicine (Baltimore). 2000 Jul;794(4):241–249.
   Google Scholar
• Christodoulou MI, Kapsogeorgou EK, Moutsopoulos HM. Characteristics of the minor salivary gland infiltrates in Sjögren’s syndrome. J Autoimmun. 2010 Jun;344(4):400–407.
   Google Scholar
• Christodoulou MI, Kapsogeorgou EK, Moutsopoulos NM, et al. Foxp3+ T-regulatory cells in Sjogren’s syndrome: correlation with the grade of the autoimmune lesion and certain adverse prognostic factors. Am J Pathol. 2008 Nov;1735(5):1389–1396.
   Google Scholar
• Stergiou IE, Poulaki A, Voulgarelis M. Pathogenetic mechanisms implicated in Sjögren’s syndrome lymphomagenesis: a review of the literature. J Clin Med. 2020 Nov 24;9(12):3794.
   Web of Science ®Google Scholar
• Zintzaras E, Voulgarelis M, Moutsopoulos HM. The risk of lymphoma development in autoimmune diseases: a meta-analysis. Arch Intern Med. 2005 Nov 14;16520(20):2337–2344.
   Google Scholar
• Singh AG, Singh S, Matteson EL. Rate, risk factors and causes of mortality in patients with Sjögren’s syndrome: a systematic review and meta-analysis of cohort studies. Rheumatology (Oxford). 2016 Mar;553:450–460.
   Google Scholar
• Brito-Zerón P, Kostov B, Solans R, et al. Systemic activity and mortality in primary Sjögren syndrome: predicting survival using the EULAR-SS disease activity index (ESSDAI) in 1045 patients. Ann Rheum Dis. 2016 Feb;752(2):348–355.
   Google Scholar
• Pertovaara M, Pukkala E, Laippala P, et al. A longitudinal cohort study of Finnish patients with primary Sjögren’s syndrome: clinical, immunological, and epidemiological aspects. Ann Rheum Dis. 2001;605(5):467–472.
   Google Scholar
• Theander E, Manthorpe R, Jacobsson LT. Mortality and causes of death in primary Sjögren’s syndrome: a prospective cohort study. Arthritis Rheum. 2004 Apr;50(4):1262–1269.
   PubMed Web of Science ®Google Scholar
• Chatzis LG, Stergiou IE, Goules AV, et al. Clinical picture, outcome and predictive factors of lymphoma in primary Sjögren’s syndrome: results from a harmonized dataset (1981–2021). Rheumatology. 2022 Aug 30;61(9):3576–3585.
   Web of Science ®Google Scholar
• Baimpa E, Dahabreh IJ, Voulgarelis M, et al. Hematologic manifestations and predictors of lymphoma development in primary Sjögren syndrome: clinical and pathophysiologic aspects. Medicine (Baltimore). 2009 Sep;885(5):284–293.
   Google Scholar
• Voulgarelis M, Ziakas PD, Papageorgiou A, et al. Prognosis and outcome of non-Hodgkin lymphoma in primary Sjögren syndrome. Medicine (Baltimore). 2012 Jan;911(1):1–9.
   Google Scholar
• Hernández-Molina G, Kostov B, Brito-Zerón P, et al. Characterization and outcomes of 414 patients with primary SS who developed hematological malignancies. Rheumatology (Oxford). 2022 Apr 6.
   Google Scholar
• Papageorgiou A, Ziogas DC, Mavragani CP, et al. Predicting the outcome of Sjogren’s syndrome-associated non-Hodgkin’s lymphoma patients. PLoS One. 2015;102(2):e0116189.
   Google Scholar
• Vasaitis L, Nordmark G, Theander E, et al. Population-based study of patients with primary Sjögren’s syndrome and lymphoma: lymphoma subtypes, clinical characteristics, and gender differences. Scand J Rheumatol. 2020 May;493(3):225–232.
   Google Scholar
• Chiu Y-H, Chung C-H, Lin K-T, et al. Predictable biomarkers of developing lymphoma in patients with Sjögren syndrome: a nationwide population-based cohort study. Oncotarget. 2017;830(30):50098–50108.
   Google Scholar
• Theander E, Henriksson G, Ljungberg O, et al. Lymphoma and other malignancies in primary Sjögren’s syndrome: a cohort study on cancer incidence and lymphoma predictors. Ann Rheum Dis. 2006 Jun;656(6):796–803.
   Google Scholar
• Gorodetskiy VR, Probatova NA, Radenska-Lopovok SG, et al. Clonal relationship of marginal zone lymphoma and diffuse large B-cell lymphoma in Sjogren’s syndrome patients: case series study and review of the literature. Rheumatol Int. 2020 Mar;403(3):499–506.
   Google Scholar
• Goules AV, Tzioufas AG. Lymphomagenesis in Sjögren’s syndrome: predictive biomarkers towards precision medicine. Autoimmun Rev. 2019 Feb;182(2):137–143.
   Google Scholar
• De Vita S, Gandolfo S. Predicting lymphoma development in patients with Sjögren’s syndrome. Expert Rev Clin Immunol. 2019 Sep;159(9):929–938.
   Google Scholar
• Davidson BK, Kelly CA, Griffiths ID. Primary Sjögren’s syndrome in the North East of England: a long-term follow-up study. Rheumatology (Oxford). 1999 Mar;383(3):245–253.
   Google Scholar
• Ramos-Casals M, Cervera R, Font J, et al. Young onset of primary Sjögren’s syndrome: clinical and immunological characteristics. Lupus. 1998 [1998 March 01];73(3):202–206.
   Google Scholar
• Solans-Laqué R, López-Hernandez A, Bosch-Gil JA, et al. Risk, predictors, and clinical characteristics of lymphoma development in primary Sjögren’s syndrome. Semin Arthritis Rheum. 2011 Dec;413(3):415–423.
   Google Scholar
• Johnsen SJ, Brun JG, Gøransson LG, et al. Risk of non-Hodgkin’s lymphoma in primary Sjögren’s syndrome: a population-based study. Arthritis Care Res (Hoboken). 2013 May;655(5):816–821.
   Google Scholar
• Brito-Zerón P, Ramos-Casals M, Bove A, et al. Predicting adverse outcomes in primary Sjogren’s syndrome: identification of prognostic factors. Rheumatology (Oxford). 2007 Aug;468(8):1359–1362.
   Google Scholar
• Fragkioudaki S, Mavragani CP, Moutsopoulos HM. Predicting the risk for lymphoma development in Sjogren syndrome: an easy tool for clinical use. Medicine (Baltimore). 2016;95(25):e3766.
   PubMed Web of Science ®Google Scholar
• Goules AV, Argyropoulou OD, Pezoulas VC, et al. Primary Sjögren’s syndrome of early and late onset: distinct clinical phenotypes and lymphoma development. Front Immunol. 2020;11:594096.
   PubMed Web of Science ®Google Scholar
• Brito-Zerón P, Kostov B, Fraile G, et al. Characterization and risk estimate of cancer in patients with primary Sjögren syndrome. J Hematol Oncol. 2017 April 17;10(1):90.
   Web of Science ®Google Scholar
• Ramírez Sepúlveda JI, Kvarnström M, Eriksson P, et al. Long-term follow-up in primary Sjögren’s syndrome reveals differences in clinical presentation between female and male patients. Biol Sex Differ. 2017 Aug 8;81(1):25.
   Google Scholar
• Baldini C, Pepe P, Luciano N, et al. A clinical prediction rule for lymphoma development in primary Sjögren’s syndrome. J Rheumatol. 2012 Apr;394(4):804–808.
   Google Scholar
• Chatzis L, Pezoulas VC, Ferro F, et al.Sjögren’s syndrome: the clinical spectrum of male patients.J Clin Med. 2020Aug 12;98(8):2620.
   Google Scholar
• Weng MY, Huang YT, Liu MF, et al. Incidence of cancer in a nationwide population cohort of 7852 patients with primary Sjogren’s syndrome in Taiwan. Ann Rheum Dis. 2012 Apr;714(4):524–527.
   Google Scholar
• Gondran G, Fauchais A, Lambert M, et al. Primary Sjogren’s syndrome in men. Scand J Rheumatol. 2008 Jul-Aug;374(4):300–305.
   Google Scholar
• Kassan SS, Thomas TL, Moutsopoulos HM, et al. Increased risk of lymphoma in sicca syndrome. Ann Intern Med. 1978 Dec;896(6):888–892.
   Google Scholar
• Abrol E, González-Pulido C, Praena-Fernández JM, et al. A retrospective study of long-term outcomes in 152 patients with primary Sjogren’s syndrome: 25-year experience. Clin Med (Lond). 2014 Apr;142(2):157–164.
   Google Scholar
• De Vita S, Gandolfo S, Zandonella Callegher S, et al. The evaluation of disease activity in Sjögren’s syndrome based on the degree of MALT involvement: glandular swelling and cryoglobulinaemia compared to ESSDAI in a cohort study. Clin Exp Rheumatol. 2018 May-Jun;36(3):150–156.
   PubMed Web of Science ®Google Scholar
• Nocturne G, Virone A, Ng WF, et al. Rheumatoid factor and disease activity are independent predictors of lymphoma in primary Sjögren’s syndrome. Arthritis Rheumatol. 2016 Apr;684(4):977–985.
   Google Scholar
• Risselada AP, Kruize AA, Bijlsma JW. Clinical features distinguishing lymphoma development in primary Sjögren’s syndrome – a retrospective cohort study. Semin Arthritis Rheum. 2013 Oct;432(2):171–177.
   Google Scholar
• Sutcliffe N, Inanc M, Speight P, et al. Predictors of lymphoma development in primary Sjögren’s syndrome. Semin Arthritis Rheum. 1998 Oct;282(2):80–87.
   Google Scholar
• Zhang W, Feng S, Yan S, et al. Incidence of malignancy in primary Sjogren’s syndrome in a Chinese cohort. Rheumatology (Oxford). 2010 Mar;493(3):571–577.
   Google Scholar
• Quartuccio L, Isola M, Baldini C, et al. Biomarkers of lymphoma in Sjögren’s syndrome and evaluation of the lymphoma risk in prelymphomatous conditions: results of a multicenter study. J Autoimmun. 2014 Jun;51:75–80.
   PubMed Web of Science ®Google Scholar
• Ramos-Casals M, Anaya JM, García-Carrasco M, et al. Cutaneous vasculitis in primary Sjögren syndrome: classification and clinical significance of 52 patients. Medicine (Baltimore). 2004 Mar;832(2):96–106.
   Google Scholar
• Retamozo S, Gheitasi H, Quartuccio L, et al. Cryoglobulinaemic vasculitis at diagnosis predicts mortality in primary Sjögren syndrome: analysis of 515 patients. Rheumatology (Oxford). 2016 Aug;558(8):1443–1451.
   Google Scholar
• Voulgarelis M, Dafni UG, Isenberg DA, et al. Malignant lymphoma in primary Sjögren’s syndrome: a multicenter, retrospective, clinical study by the European Concerted Action on Sjögren’s syndrome. Arthritis Rheum. 1999 Aug;428(8):1765–1772.
   Google Scholar
• Quartuccio L, Isola M, Baldini C, et al. Clinical and biological differences between cryoglobulinaemic and hypergammaglobulinaemic purpura in primary Sjögren’s syndrome: results of a large multicentre study. Scand J Rheumatol. 2015;441(1):36–41.
   Google Scholar
• Bende RJ, Slot LM, Hoogeboom R, et al. Stereotypic rheumatoid factors that are frequently expressed in mucosa-associated lymphoid tissue-type lymphomas are rare in the labial salivary glands of patients with Sjögren’s syndrome. Arthritis Rheumatol. 2015 Apr;674(4):1074–1083.
   Google Scholar
• Tzioufas AG, Boumba DS, Skopouli FN, et al. Mixed monoclonal cryoglobulinemia and monoclonal rheumatoid factor cross-reactive idiotypes as predictive factors for the development of lymphoma in primary Sjögren’s syndrome. Arthritis Rheum. 1996 May;395(5):767–772.
   Google Scholar
• De Vita S, Boiocchi M, Sorrentino D, et al. Characterization of prelymphomatous stages of B cell lymphoproliferation in Sjögren’s syndrome. Arthritis Rheum. 1997 Feb;402(2):318–331.
   Google Scholar
• Kipps TJ, Tomhave E, Chen PP, et al. Molecular characterization of a major autoantibody-associated cross-reactive idiotype in Sjogren’s syndrome. J Immunol. 1989;14212:4261.
   Google Scholar
• Fox RI, Chen P, Carson DA, et al. Expression of a cross-reactive idiotype on rheumatoid factor in patients with Sjogren’s syndrome. J Immunol. 1986;1362:477–483.
   Google Scholar
• Bende RJ, Aarts WM, Riedl RG, et al. Among B cell non-Hodgkin’s lymphomas, MALT lymphomas express a unique antibody repertoire with frequent rheumatoid factor reactivity. J Exp Med. 2005 [2018 Apr 18];201(8):1229–1241.
   PubMed Web of Science ®Google Scholar
• Miklos JA, Swerdlow SH, Bahler DW. Salivary gland mucosa-associated lymphoid tissue lymphoma immunoglobulin VH genes show frequent use of V1-69 with distinctive CDR3 features. Blood. 2000;9512(12):3878–3884.
   Google Scholar
• Fayyaz A, Kurien BT, Scofield RH. Autoantibodies in Sjögren’s syndrome. Rheum Dis Clin North Am. 2016 Aug;423(3):419–434.
   Google Scholar
• Scofield RH, Fayyaz A, Kurien BT, et al. Prognostic value of Sjögren’s syndrome autoantibodies. J Lab Precis Med. 2018 Oct;3:92.
   Google Scholar
• Gerli R, Muscat C, Giansanti M, et al. Quantitative assessment of salivary gland inflammatory infiltration in primary Sjögren’s syndrome: its relationship to different demographic, clinical and serological features of the disorder. Br J Rheumatol. 1997 Sep;369(9):969–975.
   Google Scholar
• Nardi N, Brito-Zerón P, Ramos-Casals M, et al. Circulating auto-antibodies against nuclear and non-nuclear antigens in primary Sjögren’s syndrome. Clin Rheumatol. 2006 [2006 May 01];253(3):341–346.
   Google Scholar
• Bournia VK, Vlachoyiannopoulos PG. Subgroups of Sjögren syndrome patients according to serological profiles. J Autoimmun. 2012 Aug;391-2:15–26.
   Google Scholar
• Martel C, Gondran G, Launay D, et al. Active immunological profile is associated with systemic Sjögren’s syndrome. J Clin Immunol. 2011 Oct;315(5):840–847.
   Google Scholar
• Quartuccio L, Baldini C, Bartoloni E, et al. Anti-SSA/SSB-negative Sjögren’s syndrome shows a lower prevalence of lymphoproliferative manifestations, and a lower risk of lymphoma evolution. Autoimmun Rev. 2015 Nov;1411(11):1019–1022.
   Google Scholar
• Chatzis LG, Pezoulas V, Voulgari PV, et al. Combined seronegativity in Sjögren’s syndrome. Clin Exp Rheumatol. 2021 Nov-Dec;39(1336):80–84.
   PubMedGoogle Scholar
• Dammacco F, Sansonno D, Piccoli C, et al. The cryoglobulins: an overview. Eur J Clin Invest. 2001 Jul;317(7):628–638.
   Google Scholar
• Gorevic PD. Rheumatoid factor, complement, and mixed cryoglobulinemia. Clin Dev Immunol. 2012;2012:439018.
   PubMedGoogle Scholar
• Brito-Zerón P, Acar-Denizli N, Ng WF, et al. How immunological profile drives clinical phenotype of primary Sjögren’s syndrome at diagnosis: analysis of 10,500 patients (Sjögren Big Data Project). Clin Exp Rheumatol. 2018 May-Jun;36(1123):102–112.
   PubMedGoogle Scholar
• Quartuccio L, Baldini C, Bartoloni E, et al. Correlation between ESSDAI and ClinESSDAI in a real-life cohort of patients with Sjögren’s syndrome. Clin Exp Rheumatol. 2017;353:546–547.
   Google Scholar
• Baldini C, Pepe P, Quartuccio L, et al. Primary Sjogren’s syndrome as a multi-organ disease: impact of the serological profile on the clinical presentation of the disease in a large cohort of Italian patients. Rheumatology (Oxford). 2014 May;535(5):839–844.
   Google Scholar
• Nocturne G, Seror R, Fogel O, et al. CXCL13 and CCL11 serum levels and lymphoma and disease activity in primary Sjögren’s syndrome. Arthritis Rheumatol. 2015 Dec;6712(12):3226–3233.
   Google Scholar
• Theander E, Vasaitis L, Baecklund E, et al. Lymphoid organisation in labial salivary gland biopsies is a possible predictor for the development of malignant lymphoma in primary Sjögren’s syndrome. Ann Rheum Dis. 2011 Aug;708(8):1363–1368.
   Google Scholar
• Gottenberg JE, Seror R, Miceli-Richard C, et al. Serum levels of beta2-microglobulin and free light chains of immunoglobulins are associated with systemic disease activity in primary Sjögren’s syndrome. Data at enrollment in the prospective ASSESS cohort. PLoS One. 2013;85(5):e59868.
   Google Scholar
• Walters MT, Stevenson FK, Herbert A, et al. Urinary monoclonal free light chains in primary Sjögren’s syndrome: an aid to the diagnosis of malignant lymphoma. Ann Rheum Dis. 1986 Mar;453(3):210–219.
   Google Scholar
• Hansen A, Odendahl M, Reiter K, et al. Diminished peripheral blood memory B cells and accumulation of memory B cells in the salivary glands of patients with Sjögren’s syndrome. Arthritis Rheum. 2002 Aug;468(8):2160–2171.
   Google Scholar
• Carbone A, Gloghini A, Ferlito A. Pathological features of lymphoid proliferations of the salivary glands: lymphoepithelial sialadenitis versus low-grade B-cell lymphoma of the malt type. Pt 1. Ann Otol Rhinol Laryngol. 2000 Dec;10912(12):1170–1175.
   Google Scholar
• Fisher BA, Jonsson R, Daniels T, et al., Standardisation of labial salivary gland histopathology in clinical trials in primary Sjögren’s syndrome. Ann Rheum Dis. 2017;767(7):1161–1168.
   Google Scholar
• Brito-Zerón P, Retamozo S, Ramos-Casals M. Phenotyping Sjögren’s syndrome: towards a personalised management of the disease. Clin Exp Rheumatol. 2018 May-Jun;36(3):198–209.
   PubMed Web of Science ®Google Scholar
• Chatzis L, Goules AV, Pezoulas V, et al. A biomarker for lymphoma development in Sjogren’s syndrome: salivary gland focus score. J Autoimmun. 2021 Jul;121:102648.
   PubMed Web of Science ®Google Scholar
• Risselada AP, Kruize AA, Goldschmeding R, et al. The prognostic value of routinely performed minor salivary gland assessments in primary Sjögren’s syndrome. Ann Rheum Dis. 2014 Aug;738(8):1537–1540.
   Google Scholar
• Carubbi F, Alunno A, Cipriani P, et al. A retrospective, multicenter study evaluating the prognostic value of minor salivary gland histology in a large cohort of patients with primary Sjögren’s syndrome. Lupus. 2015 Mar;243(3):315–320.
   Google Scholar
• Lee K-E, Kang J-H, Yim Y-R, et al. The significance of ectopic germinal centers in the minor salivary gland of patients with Sjögren’s syndrome. J Korean Med Sci. 2016;312(2):190–195.
   Google Scholar
• Risselada AP, Looije MF, Kruize AA, et al. The role of ectopic germinal centers in the immunopathology of primary Sjögren’s syndrome: a systematic review. Semin Arthritis Rheum. 2013 Feb;424(4):368–376.
   Google Scholar
• Sène D, Ismael S, Forien M, et al. Ectopic germinal center-like structures in minor salivary gland biopsy tissue predict lymphoma occurrence in patients with primary Sjögren’s syndrome. Arthritis Rheumatol. 2018 Sep;709(9):1481–1488.
   Google Scholar
• Nishishinya MB, Pereda CA, Muñoz-Fernández S, et al. Identification of lymphoma predictors in patients with primary Sjögren’s syndrome: a systematic literature review and meta-analysis. Rheumatol Int. 2015 Jan;351(1):17–26.
   Google Scholar
• Haacke EA, van der Vegt B, Vissink A, et al. Germinal centres in diagnostic labial gland biopsies of patients with primary Sjögren’s syndrome are not predictive for parotid MALT lymphoma development. Ann Rheum Dis. 2017 Oct;7610(10):1781–1784.
   Google Scholar
• Johnsen SJ, Berget E, Jonsson MV, et al. Evaluation of germinal center-like structures and B cell clonality in patients with primary Sjögren syndrome with and without lymphoma. J Rheumatol. 2014 Nov;4111(11):2214–2222.
   Google Scholar
• Haacke EA, van der Vegt B, Vissink A, et al. Germinal centers in diagnostic biopsies of patients with primary Sjögren’s syndrome are not a risk factor for non-hodgkin’s lymphoma but a reflection of high disease activity: comment on the article by Sène et al. Arthritis Rheumatol. 2019 Jan;711(1):170–171.
   Google Scholar
• Nakshbandi U, Haacke EA, Bootsma H, et al. Bcl6 for identification of germinal centres in salivary gland biopsies in primary Sjögren’s syndrome. Oral Dis. 2020;263(3):707–710.
   Google Scholar
• Barone F, Bombardieri M, Manzo A, et al. Association of CXCL13 and CCL21 expression with the progressive organization of lymphoid-like structures in Sjögren’s syndrome. Arthritis Rheum. 2005 Jun;526(6):1773–1784.
   Google Scholar
• Bombardieri M, Barone F, Humby F, et al. Activation-induced cytidine deaminase expression in follicular dendritic cell networks and interfollicular large B cells supports functionality of ectopic lymphoid neogenesis in autoimmune sialoadenitis and MALT lymphoma in Sjögren’s syndrome. J Immunol. 2007 Oct 1;1797(7):4929–4938.
   Google Scholar
• Delli K, Haacke EA, Ihrler S, et al. Need for consensus guidelines to standardise the assessment of germinal centres and other histopathological parameters in salivary gland tissue of patients with primary Sjögren’s syndrome. Ann Rheum Dis. 2016 Jun;756(6):e32.
   Google Scholar
• Jonsson MV, Skarstein K. Follicular dendritic cells confirm lymphoid organization in the minor salivary glands of primary Sjögren’s syndrome. J Oral Pathol Med. 2008 Oct;379(9):515–521.
   Google Scholar
• Visser A, Verstappen GM, van der Vegt B, et al. Repertoire analysis of B-cells located in striated ducts of salivary glands of patients with Sjögren’s syndrome [original research]. Front Immunol. 2020 [2020 Jul 14];11:11.
   PubMed Web of Science ®Google Scholar
• De Re V, De Vita S, Gasparotto D, et al. Salivary gland B cell lymphoproliferative disorders in Sjögren’s syndrome present a restricted use of antigen receptor gene segments similar to those used by hepatitis C virus-associated non-Hodgkin's lymphomas. Eur J Immunol. 2002 Mar;323(3):903–910.
   Google Scholar
• Verstappen GM, Ice JA, Bootsma H, et al. Gene expression profiling of epithelium-associated FcRL4(+) B cells in primary Sjögren’s syndrome reveals a pathogenic signature. J Autoimmun. 2020 May;109:102439.
   PubMed Web of Science ®Google Scholar
• Haacke EA, Bootsma H, Spijkervet FKL, et al. FcRL4(+) B-cells in salivary glands of primary Sjögren’s syndrome patients. J Autoimmun. 2017 Jul;81:90–98.
   PubMed Web of Science ®Google Scholar
• Seror R, Ravaud P, Bowman SJ, et al. EULAR Sjogren’s syndrome disease activity index: development of a consensus systemic disease activity index for primary Sjogren’s syndrome. Ann Rheum Dis. 2010 Jun;696(6):1103–1109.
   Google Scholar
• Schenone LNP, C A, Mamani M, et al. Development of lymphoma in patients with primary Sjögren Syndrome OMICS publishing group. Int J Clin Rheumatology. 2019 6-;14(2):69–74.
   Google Scholar
• Mackay F, Groom JR, Tangye SG. An important role for B-cell activation factor and B cells in the pathogenesis of Sjögren’s syndrome. Curr Opin Rheumatol. 2007 Sep;195(5):406–413.
   Google Scholar
• Novak AJ, Grote DM, Stenson M, et al. Expression of BLyS and its receptors in B-cell non-Hodgkin lymphoma: correlation with disease activity and patient outcome. Blood. 2004 Oct 15;1048(8):2247–2253.
   Google Scholar
• Mariette X, Roux S, Zhang J, et al. The level of BLyS (BAFF) correlates with the titre of autoantibodies in human Sjögren’s syndrome. Ann Rheum Dis. 2003 Feb;622(2):168–171.
   Google Scholar
• Quartuccio L, Salvin S, Fabris M, et al. BLyS upregulation in Sjogren’s syndrome associated with lymphoproliferative disorders, higher ESSDAI score and B-cell clonal expansion in the salivary glands. Rheumatology (Oxford). 2013 Feb;522(2):276–281.
   Google Scholar
• Novak AJ, Slager SL, Fredericksen ZS, et al. Genetic variation in B-cell-activating factor is associated with an increased risk of developing B-cell non-Hodgkin lymphoma. Cancer Res. 2009 May 15;6910(10):4217–4224.
   Google Scholar
• Nezos A, Papageorgiou A, Fragoulis G, et al. B-cell activating factor genetic variants in lymphomagenesis associated with primary Sjogren’s syndrome. J Autoimmun. 2014 Jun;51:89–98.
   PubMed Web of Science ®Google Scholar
• Papageorgiou A, Mavragani CP, Nezos A, et al. A BAFF receptor His159Tyr mutation in Sjögren’s syndrome-related lymphoproliferation. Arthritis Rheumatol. 2015 Oct;6710(10):2732–2741.
   Google Scholar
• Kazi JU, Rönnstrand L. FMS-like tyrosine kinase 3/FLT3: from basic science to clinical implications. Physiol Rev. 2019 Jul 1;993(3):1433–1466.
   Google Scholar
• Kennedy VE, Smith CC, Bi S. FLT3 mutations in acute myeloid leukemia: key concepts and emerging controversies [review]. Front Oncol. 2020;10:10. 2020 Dec 23.
   PubMed Web of Science ®Google Scholar
• Antonysamy MA, Thomson AW. Flt3 ligand (FL) and its influence on immune reactivity. Cytokine. 2000 Feb;122(2):87–100.
   Google Scholar
• Tobón GJ, Renaudineau Y, Hillion S, et al. The Fms-like tyrosine kinase 3 ligand, a mediator of B cell survival, is also a marker of lymphoma in primary Sjögren’s syndrome. Arthritis Rheum. 2010 Nov;6211(11):3447–3456.
   Google Scholar
• Tobón GJ, Saraux A, Gottenberg JE, et al. Role of Fms-like tyrosine kinase 3 ligand as a potential biologic marker of lymphoma in primary Sjögren’s syndrome. Arthritis Rheum. 2013 Dec;6512(12):3218–3227.
   Google Scholar
• Carlsen HS, Baekkevold ES, Morton HC, et al. Monocyte-like and mature macrophages produce CXCL13 (B cell-attracting chemokine 1) in inflammatory lesions with lymphoid neogenesis. Blood. 2004 Nov 15;10410(10):3021–3027.
   Google Scholar
• Legler DF, Loetscher M, Roos RS, et al. B cell-attracting chemokine 1, a human CXC chemokine expressed in lymphoid tissues, selectively attracts B lymphocytes via BLR1/CXCR5. J Exp Med. 1998 Feb 16;1874(4):655–660.
   Google Scholar
• Allen CD, Ansel KM, Low C, et al. Germinal center dark and light zone organization is mediated by CXCR4 and CXCR5. Nat Immunol. 2004 Sep;59(9):943–952.
   Google Scholar
• Luther SA, Bidgol A, Hargreaves DC, et al. Differing activities of homeostatic chemokines CCL19, CCL21, and CXCL12 in lymphocyte and dendritic cell recruitment and lymphoid neogenesis. J Immunol. 2002 Jul 1;1691(1):424–433.
   Google Scholar
• Barone F, Bombardieri M, Rosado MM, et al. CXCL13, CCL21, and CXCL12 expression in salivary glands of patients with Sjogren’s syndrome and MALT lymphoma: association with reactive and malignant areas of lymphoid organization. J Immunol. 2008 Apr 1;1807(7):5130–5140.
   Google Scholar
• Traianos EY, Locke J, Lendrem D, et al. Serum CXCL13 levels are associated with lymphoma risk and lymphoma occurrence in primary Sjögren’s syndrome. Rheumatol Int. 2020 Apr;40(4):541–548.
   PubMed Web of Science ®Google Scholar
• Chatzis L, Goules AV, Stergiou IE, et al. Serum, but not saliva, CXCL13 levels associate with infiltrating CXCL13+ cells in the minor salivary gland lesions and other histologic parameters in patients with Sjögren’s syndrome. Front Immunol. 2021;12:705079.
   PubMed Web of Science ®Google Scholar
• Wertz IE, O’Rourke KM, Zhou H, et al. De-ubiquitination and ubiquitin ligase domains of A20 downregulate NF-kappaB signalling. Nature. 2004 Aug 5;4307000(7000):694–699.
   Google Scholar
• Sisto M, Lisi S, Lofrumento DD, et al. A failure of TNFAIP3 negative regulation maintains sustained NF-κB activation in Sjögren’s syndrome. Histochem Cell Biol. 2011 Jun;135(6):615–625.
   PubMed Web of Science ®Google Scholar
• Johnsen SJ, Gudlaugsson E, Skaland I, et al. Low protein A20 in minor salivary glands is associated with lymphoma in primary Sjögren’s syndrome. Scand J Immunol. 2016 Mar;833(3):181–187.
   Google Scholar
• Nocturne G, Boudaoud S, Miceli-Richard C, et al. Germline and somatic genetic variations of TNFAIP3 in lymphoma complicating primary Sjogren’s syndrome. Blood. 2013;12225(25):4068–4076.
   Google Scholar
• Nezos A, Gkioka E, Koutsilieris M, et al. TNFAIP3 F127C coding variation in Greek primary Sjogren’s syndrome patients. J Immunol Res. 2018 [2018 December 19];2018:6923213.
   PubMed Web of Science ®Google Scholar
• Nezos A, Gravani F, Tassidou A, et al. Type I and II interferon signatures in Sjogren’s syndrome pathogenesis: contributions in distinct clinical phenotypes and Sjogren’s related lymphomagenesis. J Autoimmun. 2015 Sep;63:47–58.
   PubMed Web of Science ®Google Scholar
• Humphries B, Yang C. The microRNA-200 family: small molecules with novel roles in cancer development, progression and therapy. Oncotarget. 2015 Mar 30;69(9):6472–6498.
   Google Scholar
• Gourzi VC, Kapsogeorgou EK, Kyriakidis NC, et al. Study of microRNAs (miRNAs) that are predicted to target the autoantigens Ro/SSA and La/SSB in primary Sjögren’s Syndrome. Clin Exp Immunol. 2015;1821(1):14–22.
   Google Scholar
• Kapsogeorgou EK, Papageorgiou A, Protogerou AD, et al. Low miR200b-5p levels in minor salivary glands: a novel molecular marker predicting lymphoma development in patients with Sjögren’s syndrome. Ann Rheum Dis. 2018 Aug;778:1200–1207.
   Google Scholar
• Ziegler SF, Artis D. Sensing the outside world: TSLP regulates barrier immunity. Nat Immunol. 2010 Apr;114(4):289–293.
   Google Scholar
• Gandolfo S, Bulfoni M, Fabro C, et al. Thymic stromal lymphopoietin expression from benign lymphoproliferation to malignant B-cell lymphoma in primary Sjögren’s syndrome. Clin Exp Rheumatol. 2019 May-Jun;37(3):55–64.
   PubMed Web of Science ®Google Scholar
• Gandolfo S, Fabro C, Kapsogeorgou E, et al. Validation of thymic stromal lymphopoietin as a biomarker of primary Sjögren’s syndrome and related lymphoproliferation: results in independent cohorts. Clin Exp Rheumatol. 2020 Jul-Aug;38(1264):189–194.
   PubMedGoogle Scholar
• Pelegrin P. P2X7 receptor and the NLRP3 inflammasome: partners in crime. Biochem Pharmacol. 2021 ;187:114385. 2021 May 01.
   PubMed Web of Science ®Google Scholar
• Baldini C, Santini E, Rossi C, et al. The P2X7 receptor-NLRP3 inflammasome complex predicts the development of non-Hodgkin’s lymphoma in Sjogren’s syndrome: a prospective, observational, single-centre study. J Intern Med. 2017 Aug;2822(2):175–186.
   Google Scholar
• Vakrakou AG, Boiu S, Ziakas PD, et al. Systemic activation of NLRP3 inflammasome in patients with severe primary Sjögren’s syndrome fueled by inflammagenic DNA accumulations. J Autoimmun. 2018 Jul;91:23–33.
   PubMed Web of Science ®Google Scholar
• Nezos A, Makri P, Gandolfo S, et al. TREX1 variants in Sjogren’s syndrome related lymphomagenesis. Cytokine. 2020 Aug;132:154781.
   PubMed Web of Science ®Google Scholar
• Cinoku II,Piperi E, Verrou K-M, et al. Interferon (IFN)-stimulated gene 15: a novel biomarker for lymphoma development in Sjögren’s syndrome. J Autoimmun. 2021 Sep;123:102704.
   PubMed Web of Science ®Google Scholar
• Hudson LE, Allen RL. Leukocyte Ig-Like receptors – a model for MHC class I disease associations [mini review]. Front Immunol. 2016 July 25;7:281.
   PubMed Web of Science ®Google Scholar
• Low HZ, Reuter S, Topperwien M, et al. Association of the LILRA3 deletion with B-NHL and functional characterization of the immunostimulatory molecule. PloS one. 2013;812:e81360–e81360.
   Google Scholar
• Argyriou E, Nezos A, Roussos P, et al.Leukocyte immunoglobulin-like receptor A3 (LILRA3): a novel marker for lymphoma development among patients with young onset Sjogren’s Syndrome.J Clin Med. 2021 Feb 8;10(4):644.
   Web of Science ®Google Scholar
• Fragkioudaki S, Nezos A, Souliotis VL, et al. MTHFR gene variants and non-MALT lymphoma development in primary Sjogren’s syndrome. Sci Rep. 2017;71:7354.
   Google Scholar
• Mavragani CP, Nezos A, Sagalovskiy I, et al. Defective regulation of L1 endogenous retroelements in primary Sjogren’s syndrome and systemic lupus erythematosus: role of methylating enzymes. J Autoimmun. 2018 Mar;88:75–82.
   PubMed Web of Science ®Google Scholar
• Ciccacci C, Perricone C, Ceccarelli F, et al. A multilocus genetic study in a cohort of Italian SLE patients confirms the association with STAT4 gene and describes a new association with HCP5 gene. PloS one. 2014;911(11):e111991–e111991.
   Google Scholar
• Colafrancesco S, Ciccacci C, Priori R, et al. STAT4, TRAF3IP2, IL10, and HCP5 polymorphisms in Sjögren’s syndrome: association with disease susceptibility and clinical aspects. J Immunol Res. 2019;2019:7682827.
   PubMed Web of Science ®Google Scholar
• Tetta C, Bussolino F, Modena V, et al. Release of platelet-activating factor in systemic lupus erythematosus. Int Arch Allergy Appl Immunol. 1990;913(3):244–256.
   Google Scholar
• Kald B, Smedh K, Olaison G, et al. Platelet-activating factor acetylhydrolase activity in intestinal mucosa and plasma of patients with Crohn’s disease. Digestion. 1996 Nov-Dec;576(6):472–477.
   Google Scholar
• Nezos A, Skarlis C, Psarrou A, et al. Lipoprotein-associated phospholipase A2: a novel contributor in Sjögren’s syndrome-related lymphoma? Front Immunol. 2021;12:683623.
   PubMed Web of Science ®Google Scholar
• Barrington SF, Mikhaeel NG, Kostakoglu L, et al. Role of imaging in the staging and response assessment of lymphoma: consensus of the international conference on malignant lymphomas imaging working group. J Clin Oncol. 2014 Sep 20;3227(27):3048–3058.
   Google Scholar
• Devauchelle-Pensec V, Zabotti A, Carvajal-Alegria G, et al. Salivary gland ultrasonography in primary Sjögren’s syndrome: opportunities and challenges. Rheumatology (Oxford). 2021 Aug;60(8):3522–3527 .
   Web of Science ®Google Scholar
• Jousse-Joulin S, D’Agostino MA, Nicolas C, et al. Video clip assessment of a salivary gland ultrasound scoring system in Sjögren’s syndrome using consensual definitions: an OMERACT ultrasound working group reliability exercise. Ann Rheum Dis. 2019 Jul;787(7):967–973.
   Google Scholar
• Theander E, Mandl T. Primary Sjögren’s syndrome: diagnostic and prognostic value of salivary gland ultrasonography using a simplified scoring system. Arthritis Care Res (Hoboken). 2014 Jul;667(7):1102–1107.
   Google Scholar
• Coiffier G, Martel A, Albert JD, et al. Ultrasonographic damages of major salivary glands are associated with cryoglobulinemic vasculitis and lymphoma in primary Sjogren’s syndrome: are the ultrasonographic features of the salivary glands new prognostic markers in Sjogren’s syndrome? Ann Rheum Dis. 2021 Jul;807(7):e111.
   Google Scholar
• Lorenzon M, Tulipano Di Franco F, Zabotti A, et al. Sonographic features of lymphoma of the major salivary glands diagnosed with ultrasound-guided core needle biopsy in Sjögren’s syndrome. Clin Exp Rheumatol. 2021 Nov-Dec;39(1336):175–183.
   PubMedGoogle Scholar
• Bădărînză M, Serban O, Maghear L, et al. Shear wave elastography as a new method to identify parotid lymphoma in primary Sjögren syndrome patients: an observational study. Rheumatol Int. 2020 Aug;408(8):1275–1281.
   Google Scholar
• Baldini C, Zabotti A, Filipovic N, et al. Imaging in primary Sjögren’s syndrome: the ‘obsolete and the new.’ Clin Exp Rheumatol. 2018 May-Jun;36(3):215–221.
   PubMed Web of Science ®Google Scholar
• Grevers G, Ihrler S, Vogl TJ, et al. A comparison of clinical, pathological and radiological findings with magnetic resonance imaging studies of lymphomas in patients with Sjögren’s syndrome. Eur Arch Otorhinolaryngol. 1994;2514(4):214–217.
   Google Scholar
• Zhu L, Wang P, Yang J, et al. Non-Hodgkin lymphoma involving the parotid gland: CT and MR imaging findings. Dentomaxillofac Radiol. 2013;429(9):20130046.
   Google Scholar
• El Miedany YM, Ahmed I, Mourad HG, et al. Quantitative ultrasonography and magnetic resonance imaging of the parotid gland: can they replace the histopathologic studies in patients with Sjogren’s syndrome? Joint Bone Spine. 2004 Jan;711(1):29–38.
   Google Scholar
• Tonami H, Matoba M, Kuginuki Y, et al. Clinical and imaging findings of lymphoma in patients with Sjögren syndrome. J Comput Assist Tomogr. 2003 Jul-Aug;274(4):517–524.
   Google Scholar
• Tonami H, Matoba M, Yokota H, et al. Mucosa-associated lymphoid tissue lymphoma in Sjögren’s syndrome: initial and follow-up imaging features. AJR Am J Roentgenol. 2002 Aug;1792(2):485–489.
   Google Scholar
• Olsson P, Ekblad F, Hassler A, et al. Complications after minor salivary gland biopsy: a retrospective study of 630 patients from two Swedish centres. Scand J Rheumatol. 2022;1–9.10.1080/03009742.2021.1999671.
   PubMed Web of Science ®Google Scholar
• Pijpe J, Kalk WWI, van der Wal JE, et al. Parotid gland biopsy compared with labial biopsy in the diagnosis of patients with primary Sjögren’s syndrome. Rheumatology. 2007;462:335–341.
   Google Scholar
• van Nimwegen Jf, van Ginkel Ms, Arends S, et al. Validation of the ACR-EULAR criteria for primary Sjögren’s syndrome in a Dutch prospective diagnostic cohort. Rheumatology. 2018;575(5):818–825.
   Google Scholar
• Mossel E, Delli K, van Nimwegen JF, et al. Ultrasonography of major salivary glands compared with parotid and labial gland biopsy and classification criteria in patients with clinically suspected primary Sjögren’s syndrome. Ann Rheum Dis. 2017 Nov;7611(11):1883–1889.
   Google Scholar
• Colella G, Cannavale R, Vicidomini A, et al. Salivary gland biopsy: a comprehensive review of techniques and related complications. Rheumatology (Oxford). 2010 Nov;4911(11):2117–2121.
   Google Scholar
• Kourou KD, Pezoulas VC, Georga EI, et al. Predicting lymphoma development by exploiting genetic variants and clinical findings in a machine learning-based methodology with ensemble classifiers in a cohort of Sjögren’s syndrome patients. IEEE Open J Eng Med Biol. 2020;1:49–56.
   PubMedGoogle Scholar